Budget Impact Analysis of the Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors – Nilotinib in the First and Second Lines of Therapy
Abstract
Authors
A Kolbin M Frolov A Kurylev I Vilum Y Balykina M Proskurin